Literature DB >> 6832192

Elimination of cefroxadine (CGP-9000) from patients undergoing dialysis.

M J Nieto, J M Lanao, A Dominguez-Gil, J M Tabernero, J F Macias.   

Abstract

The pharmacokinetics of cefroxadine was studied in 17 patients with terminal renal impairment, 10 of whom were undergoing 5 h dialysis sessions. The antibiotic was administered as a single oral dose of 500 mg. Cefroxadine followed a single compartment open kinetic model. During the interdialysis period in patients with terminal renal impairment, an average Cmax of 26.59 micrograms/ml and a tmax of 3.65 h were reached, which are greater than in patients with normal renal function. The serum half-life was reduced from 23.55 h in the interdialysis periods to 3.40 h during the dialysis sessions. The average extraction coefficient was 0.249. It is recommended that a 500 mg dose cefroxadine should be administered at the end of each dialysis session if the interdialysis period is 48 h.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6832192     DOI: 10.1007/bf00613936

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

Review 1.  Pharmacokinetics and clinical use of cephalosporin antibiotics.

Authors:  C H Nightingale; D S Greene; R Quintiliani
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  Per cent absorbed time plots derived from blood level and/or urinary excretion data.

Authors:  J G WAGNER; E NELSON
Journal:  J Pharm Sci       Date:  1963-06       Impact factor: 3.534

3.  Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure.

Authors:  R Bloch; J J Szwed; R S Sloan; F C Luft
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

4.  Influence of probenecid and food on the bioavailability of cephradine in normal male subjects.

Authors:  T W Mischler; A A Sugerman; D A Willard; L J Brannick; E S Neiss
Journal:  J Clin Pharmacol       Date:  1974 Nov-Dec       Impact factor: 3.126

5.  The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin.

Authors:  R R Bailey; P E Gower; C H Dash
Journal:  Postgrad Med J       Date:  1970-10       Impact factor: 2.401

6.  Pharmacokinetics of cephalexin in renal insufficiency.

Authors:  C Regamey; L Humair
Journal:  Postgrad Med J       Date:  1971-02       Impact factor: 2.401

7.  Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis.

Authors:  S J Berman; W H Boughton; J G Sugihara; E G Wong; M M Sato; A W Siemsen
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

8.  Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000.

Authors:  H Lode; R Stahlmann; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

9.  Pharmacokinetics of cephacetrile in patients undergoing haemodialysis.

Authors:  A Dominguez-Gil; J M Lanao; J M Tabernero; J L Rodriguez Commes; S de Castro
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

10.  Cefadroxil kinetics in patients with renal insufficiency.

Authors:  R E Cutler; A D Blair; M R Kelly
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

View more
  1 in total

Review 1.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.